Introduction：Basic information about CAS 191282-48-1|trans-C75, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | trans-C75 |
|---|
| CAS Number | 191282-48-1 | Molecular Weight | 254.322 |
|---|
| Density | 1.1±0.1 g/cm3 | Boiling Point | 432.1±45.0 °C at 760 mmHg |
|---|
| Molecular Formula | C14H22O4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 159.2±22.2 °C |
|---|
Names
| Name | trans-Tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylic Acid |
|---|
| Synonym | More Synonyms |
|---|
trans-C75 BiologicalActivity
| Description | C75 trans is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM. |
|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Fatty Acid Synthase (FAS)Research Areas >>Cancer |
|---|
| Target | IC50: 35 μM (PC3 cell)[1] |
|---|
| In Vitro | C75 inhibits PC3 cell growht with an IC50 of 35 μM at 24 h. C75 (10-50 μM) also reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC50 of 50 μM[1]. (-)-C75 inhibits FAS activity and has a cytotoxic effect on tumor cell lines, without affecting food consumption. (+)-C75 inhibits CPT1 and its administration produces anorexia, suggesting that central inhibition of CPT1 is essential for the anorectic effect of C75. The differential activity of C75 enantiomers may lead to the development of potential new specific drugs for cancer and obesity[2]. |
|---|
| In Vivo | C75 blocks fasting-induced c-Fos expression in the arcuate nucleus (Arc), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) 10–24 h after i.p. injection. Intraperitoneal administration of C75 at 30 mg/kg body weight inhibits food intake of mice by ≥95% within 2 h after i.p. injection[3]. C75-treated DIO mice has a 50% greater weight loss, and a 32.9% increased production of energy because of fatty acid oxidation. C75 treatment of rodent adipocytes and hepatocytes and human breast cancer cells increases fatty acid oxidation and ATP levels by increasing CPT-1 activity, even in the presence of elevated concentrations of malonyl-CoA[4]. |
|---|
| Cell Assay | Cells are seeded in 96-well plates and incubated for 2 days to allow exponential phase growth. Cells are then ished twice with PBS and treated with C75. After 24 or 48 h incubation, MTT is added to a final concentration of 0.5 mg/ml and cultures are incubated for 2 h. Cells are then solubilized with DMSO before measuring absorbance at 570 nm. Cell growth is also measured, using MTT assay, every 24 h up to 96 h[1]. |
|---|
| Animal Admin | Mice: C75 is administered either by i.p. (i.p.; 30 mg/kg of body weight) or i.c.v. (10 μg in 3 μL of RPMI medium 1640) injection. One, 11.5, and 24 h after i.p. injection, cumulative food intake is measured, mice are killed, brains are sectioned, and slices are subjected to immunohistochemical staining for c-Fos. All i.p. injections are given 1 h before the start of the dark cycle. For i.c.v. injection, mice are anesthetized with metofane and given 3 μl of RPMI medium 1640 (control) or C75 in RPMI medium 1640 into the lateral ventricle with a calibrated 10-μl Hamilton syringe[3]. |
|---|
| References | [1]. Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. [2]. Makowski K, et al. Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality. 2013 May;25(5):281-7. [3]. Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33. [4]. Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. |
|---|
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|
| Boiling Point | 432.1±45.0 °C at 760 mmHg |
|---|
| Molecular Formula | C14H22O4 |
|---|
| Molecular Weight | 254.322 |
|---|
| Flash Point | 159.2±22.2 °C |
|---|
| Exact Mass | 254.151810 |
|---|
| PSA | 63.60000 |
|---|
| LogP | 3.65 |
|---|
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
|---|
| Index of Refraction | 1.489 |
|---|
| InChIKey | VCWLZDVWHQVAJU-NEPJUHHUSA-N |
|---|
| SMILES | C=C1C(=O)OC(CCCCCCCC)C1C(=O)O |
|---|
| Storage condition | 2-8℃ |
|---|
Safety Information
Customs
| HS Code | 2932190090 |
|---|
| Summary | 2932190090 other compounds containing an unfused furan ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
|---|
Synonyms
| C 75,(2R*,3S*)-Tetrahydro-4-methylene-2-octyl-5-oxo-3-furancarboxylicacid |
| 4-Methylene-2-octyl-5-oxotetrahydro-3-furancarboxylic acid |
| 4-Methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic acid |
| 4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid |
| 3-Furancarboxylic acid, tetrahydro-4-methylene-2-octyl-5-oxo- |
| UNII:8E9A8CTX2H |
| C75 |
